BR9708021A - Proteína substancialmente purificada composição farmacêutica sequência de ácido nucleico isolada vetor de express o de protéina auto-replicante e processos para inibir a atividade de protéinas de serina tratar uma condição e preparar um medicamento de uma proteína - Google Patents

Proteína substancialmente purificada composição farmacêutica sequência de ácido nucleico isolada vetor de express o de protéina auto-replicante e processos para inibir a atividade de protéinas de serina tratar uma condição e preparar um medicamento de uma proteína

Info

Publication number
BR9708021A
BR9708021A BR9708021A BR9708021A BR9708021A BR 9708021 A BR9708021 A BR 9708021A BR 9708021 A BR9708021 A BR 9708021A BR 9708021 A BR9708021 A BR 9708021A BR 9708021 A BR9708021 A BR 9708021A
Authority
BR
Brazil
Prior art keywords
protein
treat
prepare
nucleic acid
processes
Prior art date
Application number
BR9708021A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul P Tamburini
Gary Davis
Katherine A Delaria
Christopher W Malor
Daniel K Muller
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of BR9708021A publication Critical patent/BR9708021A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
BR9708021A 1996-03-11 1997-03-10 Proteína substancialmente purificada composição farmacêutica sequência de ácido nucleico isolada vetor de express o de protéina auto-replicante e processos para inibir a atividade de protéinas de serina tratar uma condição e preparar um medicamento de uma proteína BR9708021A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1310696P 1996-03-11 1996-03-11
US1979396P 1996-06-14 1996-06-14
US72525196A 1996-10-04 1996-10-04
PCT/US1997/003894 WO1997033996A2 (en) 1996-03-11 1997-03-10 Human bikunin

Publications (1)

Publication Number Publication Date
BR9708021A true BR9708021A (pt) 1999-07-27

Family

ID=27359773

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9708021A BR9708021A (pt) 1996-03-11 1997-03-10 Proteína substancialmente purificada composição farmacêutica sequência de ácido nucleico isolada vetor de express o de protéina auto-replicante e processos para inibir a atividade de protéinas de serina tratar uma condição e preparar um medicamento de uma proteína

Country Status (27)

Country Link
US (3) US6583108B1 (enExample)
EP (1) EP0891426B1 (enExample)
JP (2) JP3469584B2 (enExample)
KR (1) KR100356956B1 (enExample)
AR (3) AR006188A1 (enExample)
AT (1) ATE328083T1 (enExample)
AU (1) AU716923B2 (enExample)
BR (1) BR9708021A (enExample)
CA (1) CA2247888A1 (enExample)
CO (1) CO4600683A1 (enExample)
DE (1) DE69735996T2 (enExample)
DK (1) DK0891426T3 (enExample)
ES (1) ES2263174T3 (enExample)
HR (1) HRP970144B1 (enExample)
HU (1) HU226419B1 (enExample)
ID (1) ID16224A (enExample)
IL (1) IL126115A (enExample)
IN (1) IN192874B (enExample)
MY (1) MY120693A (enExample)
NZ (1) NZ331540A (enExample)
PA (1) PA8426301A1 (enExample)
PL (1) PL188387B1 (enExample)
PT (1) PT891426E (enExample)
SV (1) SV1997000018A (enExample)
TR (1) TR199801794T2 (enExample)
WO (1) WO1997033996A2 (enExample)
YU (1) YU8997A (enExample)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
EP0758682B1 (en) * 1995-07-24 2004-05-12 Mitsubishi Chemical Corporation Hepatocyte growth factor activator inhibitor
KR100356956B1 (ko) 1996-03-11 2003-03-15 베이어 코오포레이숀 사람비쿠닌
EP1005551A2 (en) * 1997-01-31 2000-06-07 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
ATE254473T1 (de) * 1998-12-22 2003-12-15 Bayer Ag Verwendung eines serinproteaseinhibitors vom kunitz-typ zur beschleunigung der schleimauflöserate
WO2000051624A2 (en) 1999-03-05 2000-09-08 The Trustees Of University Technology Corporation Methods and compositions useful in inhibiting apoptosis
US6489308B1 (en) 1999-03-05 2002-12-03 Trustees Of University Of Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions
US20040235715A1 (en) * 1999-11-12 2004-11-25 Bayer Corporation Method of producing glycosylated bikunin
IL140993A0 (en) 2000-05-15 2002-02-10 Bayer Ag Trypsin substrate and diagnostic device, and method of using same
IL140994A (en) * 2000-05-15 2005-12-18 Bayer Ag Urinary trypsin inhibitor assay containing a chelating agent
US6955921B2 (en) * 2001-04-30 2005-10-18 Bayer Corporation Trypsin substrate and diagnostic device, and method of using same
WO2003040330A2 (en) * 2001-11-05 2003-05-15 Curagen Corporation Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP2298278B1 (en) 2002-06-07 2015-11-11 Dyax Corp. Prevention and reduction of blood loss and inflammatory response
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
MXPA05007322A (es) 2003-01-06 2006-02-17 Angiochem Inc Aprotinina y analogos como portadores a traves de la barrera sangre-cerebro.
US8460243B2 (en) 2003-06-10 2013-06-11 Abbott Diabetes Care Inc. Glucose measuring module and insulin pump combination
US7244616B2 (en) 2003-06-27 2007-07-17 Bayer Pharmaceuticals Corporation Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells
US7722536B2 (en) 2003-07-15 2010-05-25 Abbott Diabetes Care Inc. Glucose measuring device integrated into a holster for a personal area network device
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
EP1704227B1 (en) * 2003-10-10 2010-01-27 Multicell Technologies, Inc. Immortalized hepatocytes
JP2007536206A (ja) * 2003-10-16 2007-12-13 バイエル・ヘルスケア・エルエルシー 尿中トリプシンインヒビターを検出するためのモノクローナル抗体
EP1586587A1 (en) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Compositions and methods for detecting angiogenesis
EP1810185A4 (en) 2004-06-04 2010-01-06 Therasense Inc DIABETES SUPPLY HOST CLIENT ARCHITECTURE AND DATA MANAGEMENT SYSTEM
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
SI1859041T2 (sl) * 2005-02-18 2015-04-30 Angiochem Inc. Polipeptidi aprotinina za prenos spojine prek krvno-moĹľganske pregrade
WO2007011693A2 (en) * 2005-07-14 2007-01-25 Medistem Laboratories, Inc. Compositions of placentally-derived stem cells for the treatment of cancer
ES2424242T3 (es) 2005-07-15 2013-09-30 Angiochem Inc. Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
US8093017B2 (en) 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
DK1981519T3 (en) * 2005-12-29 2018-02-19 Dyax Corp protease inhibition
CA2663545A1 (en) * 2006-09-19 2008-03-27 Phylogica Limited Neuroprotective peptide inhibitors of ap-1 signaling and uses thereof
US20100063146A1 (en) * 2006-11-07 2010-03-11 Medof M Edward Method for treating disorders related to complement activation
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2170932A4 (en) * 2007-06-20 2012-10-10 Phylogica Ltd COMPOSITIONS AND APPLICATIONS THEREOF IN THE TREATMENT OF ACUTE ATOMIC SYNDROME (ARDS) AND ASSOCIATED CLINICAL ILLNESSES
CA2696208A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
DE102007056231A1 (de) 2007-09-08 2009-03-12 Bayer Healthcare Ag Herstellung und Verwendung von Varianten humander Kunitz-Typ Protease-Inhibitoren (hKTPI)
MX355683B (es) * 2008-04-18 2018-04-26 Angiochem Inc Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso.
CN102245636A (zh) 2008-10-15 2011-11-16 安吉奥开米公司 用于药物递送的依托泊苷和多柔比星结合物
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
MX2011005963A (es) 2008-12-05 2011-09-01 Angiochem Inc Conjugados de neurotensina o analogos de neurotensina y sus usos.
EP2373789A4 (en) 2008-12-17 2012-08-29 Angiochem Inc MEMBRANTYP-1 MATRIX METALLOPROTEINASE INHIBITORS AND THEIR USE
AU2010203712A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
BRPI1015295A2 (pt) 2009-04-20 2016-05-31 Angiochem Inc traamento de câncer de ovário usando um agente anticâncer conjugado a um análogo angiopep-2.
RU2012103240A (ru) 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
EP2371857A1 (en) * 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
CN105713092B (zh) 2011-01-06 2019-09-10 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
US10136845B2 (en) 2011-02-28 2018-11-27 Abbott Diabetes Care Inc. Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same
KR102103476B1 (ko) 2011-06-24 2020-04-23 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
WO2013106589A1 (en) 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
CN104781276A (zh) 2012-08-14 2015-07-15 安吉奥开米公司 肽-树枝状聚合物结合物及其用途
NZ760008A (en) 2014-02-24 2023-03-31 Takeda Pharmaceuticals Co Uti fusion proteins
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
BR112018011622A2 (pt) 2015-12-11 2018-11-27 Dyax Corp método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae
EP4114428A4 (en) 2020-03-05 2025-03-12 Diamedica USA Inc. ULINASTATIN POLYPEPTIDES

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5106833A (en) 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
DE59007737D1 (de) * 1989-05-13 1995-01-05 Bayer Ag Proteinaseninhibitoren, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel.
DK408089D0 (da) 1989-08-18 1989-08-18 Novo Nordisk As Proteiner
ES2086521T3 (es) 1990-01-25 1996-07-01 Univ Washington Proteina hibrida laci-factor x.
DE69233760D1 (de) 1991-03-01 2009-06-25 Dyax Corp Inhibitoren der menschlichen Elastase von Neutrophilen
RU2054180C1 (ru) 1991-08-21 1996-02-10 Жирнов Олег Петрович (н/п) Способ лечения вирусных респираторных инфекций
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
US5747449A (en) 1992-07-13 1998-05-05 Corvas International, Inc. Bovine pancreatic trypsin inhibitor derived inhibitors of factor XA
WO1994012637A2 (en) 1992-12-02 1994-06-09 Zymogenetics, Inc. Novel human amyloid protein precursor homologue and kunitz-type inhibitors
US5436153A (en) 1992-12-02 1995-07-25 Sprecher; Cindy A. Human amyloid protein precursor homolog and Kunitz-type inhibitor
JP2769083B2 (ja) 1993-02-22 1998-06-25 日清食品株式会社 エラスターゼ阻害活性を有する新規ペプチドおよびその製造方法
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
PT737207E (pt) 1994-01-11 2005-02-28 Dyax Corp Inibidores de plasmina humana derivados de dominios kunitz
CA2180950C (en) 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US5795954A (en) 1994-03-04 1998-08-18 Genentech, Inc. Factor VIIa inhibitors from Kunitz domain proteins
WO1996003503A1 (en) 1994-07-21 1996-02-08 The Green Cross Corporation Process for producing urinary trypsin inhibitor and domains thereof, novel polypeptide related to the both, and process for producing the polypeptide
US5541228A (en) * 1994-10-14 1996-07-30 Bristol-Myers Squibb Co. Melatonergic agents
AU5854096A (en) 1995-05-08 1996-11-29 Scios Inc. Kunitz type protease inhibitors
US5786328A (en) 1995-06-05 1998-07-28 Genentech, Inc. Use of kunitz type plasma kallikrein inhibitors
EP0758682B1 (en) * 1995-07-24 2004-05-12 Mitsubishi Chemical Corporation Hepatocyte growth factor activator inhibitor
US5736364A (en) 1995-12-04 1998-04-07 Genentech, Inc. Factor viia inhibitors
KR100356956B1 (ko) 1996-03-11 2003-03-15 베이어 코오포레이숀 사람비쿠닌
EP1005551A2 (en) 1997-01-31 2000-06-07 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US6294648B1 (en) * 1999-07-20 2001-09-25 Bayer Corporation Protein having proteinase inhibitor activity

Also Published As

Publication number Publication date
US7452859B2 (en) 2008-11-18
EP0891426B1 (en) 2006-05-31
HUP9902698A2 (hu) 1999-11-29
AR053063A2 (es) 2007-04-18
IL126115A (en) 2007-03-08
CO4600683A1 (es) 1998-05-08
EP0891426A2 (en) 1999-01-20
US6583108B1 (en) 2003-06-24
PT891426E (pt) 2006-10-31
AR006188A1 (es) 1999-08-11
AU2207797A (en) 1997-10-01
TR199801794T2 (xx) 2000-07-21
DK0891426T3 (da) 2006-10-02
KR19990087697A (ko) 1999-12-27
WO1997033996A2 (en) 1997-09-18
CA2247888A1 (en) 1997-09-18
MY120693A (en) 2005-11-30
JP2001521367A (ja) 2001-11-06
ES2263174T3 (es) 2006-12-01
DE69735996D1 (de) 2006-07-06
HRP970144B1 (en) 2004-10-31
DE69735996T2 (de) 2007-02-15
HRP970144A2 (en) 1998-04-30
KR100356956B1 (ko) 2003-03-15
US20030194398A1 (en) 2003-10-16
JP3469584B2 (ja) 2003-11-25
ATE328083T1 (de) 2006-06-15
IN192874B (enExample) 2004-05-29
WO1997033996A3 (en) 1997-11-13
PA8426301A1 (es) 2000-05-24
US7019123B2 (en) 2006-03-28
HU226419B1 (en) 2008-12-29
JP2004000208A (ja) 2004-01-08
IL126115A0 (en) 1999-05-09
PL188387B1 (pl) 2005-01-31
NZ331540A (en) 1999-10-28
HUP9902698A3 (en) 2001-06-28
ID16224A (id) 1997-09-11
AR058982A1 (es) 2008-03-05
US20060172946A1 (en) 2006-08-03
SV1997000018A (es) 1999-01-14
AU716923B2 (en) 2000-03-09
PL328822A1 (en) 1999-02-15
YU8997A (sh) 1999-09-27

Similar Documents

Publication Publication Date Title
BR9708021A (pt) Proteína substancialmente purificada composição farmacêutica sequência de ácido nucleico isolada vetor de express o de protéina auto-replicante e processos para inibir a atividade de protéinas de serina tratar uma condição e preparar um medicamento de uma proteína
CZ297999A3 (cs) Arylsulfonamidy a jejich analogy, způsob jejich výroby, meziprodukty pro jejich výrobu, farmaceutické prostředky tyto látky obsahující a jejich použití
DE69830095D1 (de) Pharmazeutischer, kosmetischer oder dermo-pharmazeutischer Patch zur Verabreichung mehrerer verschiedenartiger Aktivstoffe
DK0981375T3 (da) Farmaceutiske præparater indeholdende plasmaprotein
NO20002118L (no) Cykliske aminosyrer og derivater derav som er nyttige som farmasøytiske midler
HUP0004421A3 (en) Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme
WO2000016764A3 (en) Pharmaceutical compositions comprising derivatives of sulphur acids
NO991130D0 (no) Modifiserte aminosyrer, farmas°ytiske preparater som inneholder disse forbindelsene og fremgangsmÕter for fremstilling derav
PT1019040E (pt) Inibicao da actividade de p38-quinase por meio de arilureias
HUP0003280A3 (en) Peptides having apolipoprotein a-1 agonist activity, pharmaceutical compositions comprising thereof and their use to treat dyslipidemic disorders
NO982590L (no) Metalloproteinase-inhibitorer, farmas°ytiske blandinger inneholdende dem og deres farmas°ytiske anvendelser, og fremgangsmÕter og mellomprodukter anvendelige for deres fremstilling
NO20002835D0 (no) 2-aryl-oksodihydropurinderivater, fremgangsmÕte for fremstilling av disse medisinske preparater inneholdende disse, og mellomprodukter derfor
HUP9702377A2 (hu) Önfelerősítő, gyógyszeres úton szabályozható expressziós rendszerek
NO994992L (no) Farmasöytiske blandinger med appetitt hemmende aktivitet
NO974618D0 (no) Farmasöytiske preparater for intranasal administrasjon
HUP0000492A3 (en) N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
PT826375E (pt) Utilizacao de lipidos complexos como aditivos estabilizadores para preparacoes farmaceuticas de misturas de enzimas digestivas
EP1010435A4 (en) PREPARATIONS OF NANOCAPSULES FOR THE TREATMENT OF INTRA-ARTICULAR DISEASES
FI951298A0 (fi) 2-amino-4-fenyyli-4-oksovoihappojohdannaiset, joilla on kynureninaasia ja/tai kynureniini-3-hydroksylaasia inhiboiva aktiivisuus
NO982874D0 (no) Farmas°ytiske preparater med vitamin D-analoger
HUP9903353A3 (en) 7alpha-(methyl-amino-pentyl)-estratrienes, pharmaceutical preparations which contain said 7alpha-(5-methylaminopentyl) -estratrienes and use thereof for production of drugs
BR9800913A (pt) Promotor de gene cdc25b, preparação e uso do mesmo.
HUP0002724A3 (en) Clasto-lactacystin betha-lactone, analogs and intermediates thereof, process for their preparation and pharmaceutical compositions containing them
BR9711763A (pt) Prote¡na semelhante a tnf-beta para tratamento do cÆncer de prÄstata e mol-cula de acido nucleico composi-oes farmaceutica e processos correlatos
PT801561E (pt) Composicao e metodos para a entrega transdermica de drogas labeis a acido

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements